A phase 2 trial in progress: PAMIPARIB, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency phenotype or BRCA defects.
A phase 2 trial in progress: PAMIPARIB, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency phenotype or BRCA defects.